Nouvogenes Therapeutics and Reforgene Medicine Sign MOU for Strategic Collaboration in Gene Editing Technologies
Guangzhou, China – Nouvogenes Therapeutics Co., Ltd., a pioneering biotech company based in Thailand, and Reforgene Medicine Co., Ltd., a leading gene therapy innovator from China, have officially signed a Memorandum of Understanding (MOU) to advance collaboration in the field of gene editing technologies.
The MOU was signed today, 1st July 2025, at the Royal Thai Consulate General in Guangzhou by Dr. Veerachat Petpisit, Chief Executive Officer of Nouvogenes Therapeutics, and Dr. Junbin Liang, Chief Executive Officer of Reforgene Medicine. The signing ceremony was presided over by Mr. Kajtiti Wiwatwanont, Consul General of the Kingdom of Thailand in Guangzhou.
This landmark agreement marks the beginning of a strategic partnership aimed at enhancing innovation, technology transfer, and regional access to cutting-edge gene editing therapies, with an initial focus on CRISPR-based treatments for transfusion-dependent beta-thalassemia.
Dr. Veerachat Petpisit commented, “This collaboration represents a significant milestone not only for our two companies but also for the broader goal of accelerating the availability of curative therapies in Southeast Asia. By combining the scientific excellence of Reforgene with the clinical and regulatory leadership of Nouvogenes, we are confident in our ability to deliver impactful medical solutions to patients.”
Dr. Junbin Liang added, “We are pleased to partner with Nouvogenes Therapeutics, whose strong local infrastructure and commitment to innovation align with our mission to expand access to advanced gene therapies across Asia. This MOU is a critical first step in a broader, long-term alliance.”
The collaboration reinforces Thailand’s emerging role as a regional hub for advanced therapeutics, leveraging its world-class healthcare ecosystem and regulatory advancements in support of biotech innovation.
Media Contact:
contact@nouvogenes.com
About Nouvogenes Therapeutics
Nouvogenes Therapeutics Co., Ltd. is a clinical-stage biotechnology company based in Thailand, focused on the development and commercialization of gene and cell therapies for genetically defined diseases. Its lead program is a CRISPR-based gene therapy targeting transfusion-dependent beta-thalassemia, with the mission to make advanced therapies accessible and affordable in Southeast Asia.
About Reforgene Medicine
Reforgene Medicine Co., Ltd. is a China-based biotechnology company specializing in gene editing technologies and innovative genetic therapies. The company is dedicated to developing curative treatments for inherited blood disorders and other genetic conditions using next-generation CRISPR platforms, with a strong emphasis on translational science and global collaboration.